Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Hybridoma Technology01:31

Hybridoma Technology

14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Discovery of Novel Isoxazole-Based FXR Agonists Containing a 1,2,4-Oxadiazol-5(4H)-one Ring.

Journal of medicinal chemistry·2026
Same author

Structural basis for dual targeting of μ-opioid and nociceptin/orphanin FQ receptors by Cebranopadol.

Acta pharmacologica Sinica·2026
Same author

Structural basis for lysophosphatidic acid recognition and atypical Gα<sub>q</sub> coupling by LPAR5.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases.

Nature·2026
Same author

Structural basis for a central permeation pathway in the P2X1 receptor.

Cell discovery·2026
Same author

Molecular architecture of OXGR1 reveals an evolutionary conserved mechanisms for metabolite surveillance.

The EMBO journal·2026

相关实验视频

Updated: Jun 11, 2025

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
12:55

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

18.5K

以人工智能驱动的抗体设计与生成扩散模型:当前的见解和未来的方向.

Xin-Heng He1,2, Jun-Rui Li1, James Xu3

  • 1State Key Laboratory of Drug Research and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.

Acta pharmacologica Sinica
|September 30, 2024
PubMed
概括

生成性扩散模型加速治疗抗体设计,降低成本和时间. 本综述探讨了人工智能驱动的方法,用于新的抗体生成和互补性决定区域 (CDR) 优化.

关键词:
优化CDR的优化方式抗体是对抗体的重要组成部分.一个新的抗体设计.扩散扩散是一种扩散.生成型模型的生成型模型.模型评价模型评价

更多相关视频

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

10.3K
Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity
12:31

Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity

Published on: May 1, 2018

13.6K

相关实验视频

Last Updated: Jun 11, 2025

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
12:55

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

18.5K
Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

10.3K
Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity
12:31

Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity

Published on: May 1, 2018

13.6K

科学领域:

  • 生物治疗和药物发现
  • 计算生物学和生物信息学
  • 人工智能在医学中的应用

背景情况:

  • 治疗抗体是重要的生物治疗药物,以高特异性和亲和力而闻名.
  • 优化抗体疗效面临着巨大的财务和时间限制.
  • 计算和人工智能 (AI) 方法为抗体设计挑战提供了新的解决方案.

研究的目的:

  • 对抗体设计的基于扩散的生成方法进行审查.
  • 探索新型抗体设计和CDR循环优化的应用.
  • 为在抗体工程中利用生成模型提供一个全面的资源.

主要方法:

  • 对应于抗体设计的基于扩散的生成模型的审查.
  • 对新型抗体生成方法的分析.
  • 检查互补性决定区域 (CDR) 循环优化的技术.

主要成果:

  • 扩散模型为抗体设计挑战提供了新的方法.
  • 具体的方法详细介绍了新的设计和CDR优化.
  • 讨论了评估AI生成抗体设计的评估指标.

结论:

  • 生成性扩散模型正在改变抗体设计过程.
  • 这些人工智能工具为更快,更具成本效益的抗体优化提供了潜力.
  • 该领域正在迅速发展,需要对研究人员进行全面的概述.